论文部分内容阅读
以不同种类的上皮源性恶性肿瘤患者为研究对象 ,分析肿瘤组织中p1 6 /MTS1基因纯合缺失、异常甲基化和表达缺失。发现 p1 6基因纯合缺失率为 1 4% ( 1 5 /1 0 8) ;异常甲基化检出率为 1 4% ( 8/5 8) ;p1 6蛋白表达缺失率为4 4% ( 2 8/6 3) ;按组织学分级 ,中、低分化组 p1 6蛋白表达缺失率显著高于高分化组 (P <0 .0 5 )。p1 6基因失活患者普遍预后差。肺癌、食管癌患者 p1 6基因失活者 1 7例 ,手术后 6个月内 6例死亡 ,1例转移 ;p1 6基因发生缺失和异常甲基化的 6例膀胱癌患者中 4例复发。研究结果表明 ,p1 6基因失活在上皮源性恶性肿瘤患者中是较为常见的基因变化 ,与患者的病理分级和预后有密切关系。
Different types of patients with epithelial-derived malignant tumor were selected as the research object to analyze the homozygous deletion, abnormal methylation and deletion of the p1 6 / MTS1 gene in the tumor tissue. The deletion rate of p1 6 gene was 14% (15/80). The detection rate of abnormal methylation was 14% (8/5 8). The loss of p1 6 protein was 44% According to histological grade, the loss of p16 protein expression in moderate and poorly differentiated group was significantly higher than that in well differentiated group (P <0.05). The general prognosis of patients with p16 gene inactivation is poor. Seventeen patients with lung cancer and esophageal cancer who had inactivated p1 6 gene, 6 patients died within 6 months after operation, and 1 patient had metastasis. Among the 6 patients with bladder cancer with deletion and abnormal methylation of p16 gene, 4 patients relapsed. The results show that, p16 gene inactivation in patients with epithelial-derived malignancies is a more common genetic changes, and the patient’s pathological grade and prognosis are closely related.